Skip to content

Study on the mechanism of regulating the hypothalamic CRH/CRHR1 pathway by vibro-annular abdominal massage under the brain-intestine interaction in the treatment of insomnia

Study on the mechanism of regulating the hypothalamic CRH/CRHR1 pathway by vibro-annular abdominal massage under the brain-intestine interaction in the treatment of insomnia

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004796
Enrollment
Unknown
Registered
2021-01-22
Start date
2021-06-30
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia

Interventions

Sponsors

Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Insomnia volunteers were included in the criteria 2. In line with the diagnostic criteria for chronic insomnia and deficiency of the heart and spleen, difficulty in sleeping and awakening cannot be better explained by other types of sleep disorders, and the following seven conditions are met: A. It meets the diagnostic criteria of insomnia disorder and primary insomnia with deficiency of heart and spleen; B. Aged 50-55 years; C. Did not participate in other clinical researchers; D. Signed the informed consent form and volunteered to participate in the study; E. PSQI > 7 points, AIS > 6 points, SDS and SAS = 3 times/week can only be included in this study.

Exclusion criteria

Exclusion criteria: If a subject meets any of the following conditions, he/she will not be allowed to participate in the study. 1. Insomnia patients caused by excessive anxiety and depression; 2. Respiratory related sleep disorders, circadian rhythm sleep disorders and sleep disorders; 3. Insomnia patients suffering from systemic diseases such as pain, fever, cough, etc.; 4. Patients with cardiovascular, lung, liver, kidney, hematopoietic system and other serious primary diseases; 5. Patients with mental illness; 6. The skin at the treatment site is infected or hypersensitive; 7. Patients with progressive malignant tumors or other serious wasting diseases, which are prone to co-infection and bleeding; 8. Patients who have poor compliance, or fail to receive treatment as required; 9. For some reason, it is impossible to judge the curative effect or incomplete data affects the curative effect and judgement; 10. As a result of drug abuse or drug treatment, caused by insomnia patients; 11. Sleep disorders caused by long-term excessive drinking of alcohol, coffee, strong tea, etc., and adverse life factors; 12. A pregnant, menstruating, or lactating woman.

Design outcomes

Primary

MeasureTime frame
PSQI;Resting state functional magnetic resonance imaging of the brain;SAS;Corticotropin-releasing hormone;1HNMR;?-aminobutyric acid;Norepinephrine;Electroencephalogram;Adreno-cortico-tropic-hormone;Prostaglandin 2;Cortisol;Electrocardiogram;SDS;Serotonin;

Secondary

MeasureTime frame
Routine urine;

Countries

China

Contacts

Public ContactHongshi Zhang

Department of Acupuncture and Moxibustion, Changchun University of Chinese Medicine

5503576@qq.com+86 13943018168

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026